Dyne Therapeutics is our May 2026 Hedge Fund Favorite Spotlight, with strong institutional interest, a differentiated neuromuscular pipeline, and upcoming catalyst potential. DYN was held by 13 of 34 biotech-focused hedge funds in Q4 2025, placing it well above the typical median holding level across the group. The company’s lead program, DYNE-251, is being advanced for Duchenne muscular dystrophy and is expected to reach BLA submission milestone in Q2 2026. From an investor

SUMMARY The drug-price reform focus of Congress affects biopharma stock prices The likelihood that Republicans will control at least the...

Biotech stocks are down ~40% since Jan 1, 2021, underperforming the broader markets The democratic white house and Congress since January...